Moderna and Merck's mRNA vaccine meets key cancer treatment goals in ongoing trials
The story in brief
Moderna and Merck's mRNA-based cancer vaccine, tested with Keytruda, showed interim results meeting both goals of reducing melanoma recurrence and preventing spread. Over 1.5 million Americans live with melanoma, and the treatment could benefit thousands if approved. Detailed results are expected at a medical meeting, with regulators already in talks. The development marks the first positive late-stage trial for an mRNA cancer vaccine.